Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma Shi, W., Roberge, D., Kleinberg, L., Jeyapalan, S. A., Goldlust, S., Nagpal, S., Lustgarten, L., Combs, S. E., Nishikawa, R., Reardon, D. A., Grossman, R., Glas, M. LIPPINCOTT WILLIAMS & WILKINS. 2023

View details for Web of Science ID 001053772005569